Codexis expects to recognize estimated future product revenue of $640K and research and development revenue of $6.37M in 2026, from unsatisfied performance obligations.
Bullish
Codexis advanced its ECO Synthesis platform with a new Innovation Lab and secured CDMO partnerships for scalable RNAi manufacturing, contributing to a 97% increase in R&D revenue and improved product gross margins.
Bearish
Codexis faces ongoing net losses and high customer concentration, alongside significant risks from unproven enzymatic nucleic acid synthesis technology and potential FDA regulatory challenges for its products.